$0.78
+0.01 (+0.65%)
Open$0.77
Previous Close$0.77
Day High$0.82
Day Low$0.75
52W High$1.60
52W Low$0.65
Volume—
Avg Volume205.3K
Market Cap28.40M
P/E Ratio—
EPS$-0.23
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+4,111.1% upside
Current
$0.78
$0.78
Target
$32.64
$32.64
$20.70
$32.64 avg
$34.69
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 3.47M | 3.41M | 4.58M |
| Net Income | -8,269,840 | -7,311,971 | -1,151,647 |
| Profit Margin | -238.3% | -226.4% | -25.2% |
| EBITDA | -8,079,307 | -7,540,369 | -1,556,423 |
| Free Cash Flow | — | — | -1,101,967 |
| Rev Growth | +1.8% | +1.8% | +24.2% |
| Debt/Equity | 4.08 | 4.08 | 0.58 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 37.6 | 30.39B |